Ruo Bing Xue, MD
Hematology & Oncology · Columbia, MONPI 1174973275
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,097 of the $8,008 with a category attached, or 88.6%. It is spread thinly across 39 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $3,492 and has fallen 88.1% since, to $416 in 2025.
Across 239 payments — averaging $33.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Johnson & Johnson$640
- Incyte Corporation$581
- Bayer$503
- Seagen Inc.$455
- Sanofi$395
- plus $4K from 33 others
Across 3 payments — averaging $12,681 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$35K
- E.r. Squibb & Sons, L.L.C.$3K
What the payments were for
- Food & beverage$7,09789%
- Education$91111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 56 | $1,528 |
| Johnson & Johnson | 18 | $640 |
| Incyte Corporation | 21 | $581 |
| Bayer | 12 | $503 |
| Seagen Inc. | 11 | $455 |
| Sanofi | 9 | $395 |
| E.r. Squibb & Sons, L.L.C. | 9 | $249 |
| Pfizer | 5 | $239 |
| AstraZeneca | 6 | $230 |
| Daiichi Sankyo Inc. | 11 | $211 |
| Eisai Inc. | 6 | $210 |
| Rigel Pharmaceuticals, Inc. | 3 | $206 |
| Boehringer Ingelheim | 7 | $191 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $187 |
| Regeneron Healthcare Solutions, Inc. | 4 | $183 |
| EMD Serono, Inc. | 8 | $177 |
| Histosonics, Inc. | 1 | $150 |
| Jazz Pharmaceuticals Inc. | 2 | $136 |
| Dova Pharmaceuticals | 2 | $135 |
| Beigene USA, Inc. | 4 | $134 |
| Astellas Pharma US Inc | 2 | $130 |
| Adaptive Biotechnologies Corporation | 1 | $127 |
| G1 Therapeutics, Inc. | 1 | $120 |
| Novocure Inc. | 2 | $119 |
| Intera Oncology, Inc | 1 | $118 |
| Galvanize Therapeutics, Inc | 1 | $92 |
| Foundation Medicine, Inc. | 4 | $88 |
| Merck | 5 | $82 |
| AbbVie | 4 | $78 |
| Lilly USA, LLC | 5 | $74 |
| Bristol Myers Squibb | 3 | $56 |
| Gilead | 2 | $40 |
| Ipsen Biopharmaceuticals, Inc | 2 | $33 |
| Novartis | 2 | $31 |
| Verastem, Inc. | 1 | $24 |
| Sobi, Inc | 1 | $16 |
| Coherus Oncology, Inc. | 1 | $13 |
| EUSA Pharma (US) LLC | 1 | $13 |
| Immunomedics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,008 in reported general payments places this provider in the 75th percentile of 211 hematology & oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 36 | $26,195 |
| Ondansetron Hcl | 19 | $263 |
| Oxycodone Hcl | 19 | $219 |
| Prochlorperazine Maleate | 12 | $114 |
| Prednisone | 11 | $20 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $239 | $26,19536 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 211 hematology & oncology providers in Missouri.
Other hematology & oncology in Columbia
- David SchlossmanColumbia$1.2M
- Gerhard HildebrandtColumbia$58K
- Umasankar RamadossColumbia$45K
- Liana MakarianColumbia$27K
- Andrew IliffColumbia$25K
- Cherian VergheseColumbia$20K
- Mark TungesvikColumbia$14K
- Vipul BhanderiColumbia$11K
- Elangovan BalakrishnanColumbia$10K
- Alexandre TungesvikColumbia$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.